Acrivastine
As of the edition of 20 October 2026, Acrivastine is a small molecule: marketed, first approved in 1994 (US); acts on HRH1; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1994
- Kind
- Small molecule
- Brand name
- Semprex-D
- First approved
- 25 March 1994 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Endo
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| HRH1 | Histamine H1 receptor | P35367 |